Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NYX-458 in MCI or Mild Dementia Associated With PD or LBD
NCT04148391Phase 2Active, not recruiting
- Sponsor
- Aptinyx Inc.
- Start
- Nov 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) comparing Placebo with NYX-458 30 mg (2 arms). Primary endpoints: Change from baseline in physical examination, Rates of adverse events and serious adverse events and 6 more. Started Nov 2019; status: active, not recruiting.
02
Drugs
nyx-458
03
Conditions
Parkinson's disease dementia (PDD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT04148391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148391.